La regeneración celular es un procedimiento en el cual se extraen células de la médula ósea o de la grasa las cuales son procesadas en células madre para después ser ingresadas al organismo con el fin de provocar regeneración en áreas de cuerpo que se vean afectadas por enfermedades autoinmunes o por el desgaste y la oxidación. Las tecnologías regenerativas se esfuerzan por impulsar los procesos de reparación innatos y restituir el impacto normativo. El despliegue de los principios regenerativos en la práctica está listo para marcar el comienzo de una nueva era en la atención de la salud, impulsando una innovación radical en el manejo de pacientes para abordar las necesidades de una población que envejece y se ve desafiada por la escalada de enfermedades crónicas.
Regenerative Medicine Build-Out
Regenerative technologies strive to boost innate repair processes and restitute normative impact. Deployment of regenerative principles into practice is poised to usher in a new era in health care, driving radical innovation in patient management to address the needs of an aging population challenged by escalating chronic diseases. There is urgency to design, execute, and validate viable paradigms for translating and implementing the science of regenerative medicine into tangible health benefits that provide value to stakeholders. A regenerative medicine model of care would entail scalable production and standardized application of clinical grade biotherapies supported by comprehensive supply chain capabilities that integrate sourcing and manufacturing with care delivery. Mayo Clinic has rolled out a blueprint for discovery, translation, and application of regenerative medicine therapies for accelerated adoption into the standard of care. To establish regenerative medical and surgical service lines, the Mayo Clinic model incorporates patient access, enabling platforms and delivery. Access is coordinated through a designated portal, the Regenerative Medicine Consult Service, serving to facilitate patient/provider education, procurement of biomaterials, referral to specialty services, and/or regenerative interventions, often in clinical trials. Platforms include the Regenerative Medicine Biotrust and Good Manufacturing Practice facilities for manufacture of clinical grade products for cell-based, acellular, and/or biomaterial applications. Care delivery leverages dedicated interventional suites for provision of regenerative services. Performance is tracked using a scorecard system to inform decision making. The Mayo Clinic roadmap exemplifies an integrated organization in the discovery, development, and delivery of regenerative medicine within a growing community of practice at the core of modern health care.
Regenerative medicine is at the vanguard of health care poised to offer solutions for many of today’s incurable diseases. Accordingly, there is a pressing need to develop, deploy, and demonstrate a viable framework for rollout of a regenerative medicine model of care. Translation of regenerative medicine principles into practice is feasible, yet clinical validity and utility must be established to ensure approval and adoption. Standardized and scaled-up regenerative products and services across medical and surgical specialties must in turn achieve a value-added proposition, advancing intended outcome beyond current management strategies.
Continua con la lectura en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675513/
Regenerative Medicine: On the Vanguard of Health Care
The World Health Organization reports that a staggering 36 million of the 57 million annual global deaths are due to a rampant pandemic of chronic diseases.1 Success in managing acute conditions has reduced early mortality but has concurrently precipitated a higher incidence of chronic diseases among survivors. Current evidence-based and cost-effective interventions are insufficient to meet the growing challenge posed by noncommunicable chronic conditions, driven in part by the aging of the population and the associated increase in degenerative diseases.2 Reparative therapies targeting the cause of progressive cell destruction and irreversible loss of tissue function are largely lacking. Transformation of the health care horizon will require unprecedented innovation to extend the reach of clinical practice beyond the current standard of care.
New knowledge on disease causes and cures will enable delivery of high-quality care that more effectively addresses the unmet needs of our patients.
Regenerative Medicine: Transforming Health Care
Advances in the science of regenerative medicine have begun to define a new perspective for the future of health care.3 Regenerative paradigms offer a “disruptive innovation” poised to transform medicine and surgery by providing the prospect of definitive solutions for our patients. The decisive goal of regenerative medicine is indeed to advance care from palliation to cure.
From pioneering success with bone marrow transplants to recent breakthroughs in neo-organogenesis, regenerative strategies have emerged as a promising core component of medical and surgical practice.4 Aimed at repair of disease pathobiology and restoration of organ function, forthcoming regenerative applications encompass unparalleled patient-specific diagnostic algorithms and reconstructive treatments for a range of diseases and disabilities. Across a spectrum—from congenital conditions to acquired, age-related pathologies—personalized regenerative medicine products and services promise considerable human health benefit, increased quality of life, and improved patient care.
Continua la lectura en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3127554/